Q4 2024 Heron Therapeutics Inc Earnings Call Transcript
Key Points
- Heron Therapeutics Inc (HRTX) achieved profitability for both the fourth quarter and the full year 2024, with a net income of $3.6 million for the quarter.
- The company reported a 14% year-over-year increase in net revenues, reaching $144.2 million for 2024.
- ZYNRELEF achieved record net revenues of $8.5 million in Q4 2024, marking a 33% increase from Q3.
- The gross margin improved significantly from 49% in 2023 to approximately 73% in 2024.
- Heron Therapeutics Inc (HRTX) successfully expanded the product labeling for ZYNRELEF, doubling the number of approved indicator procedures.
- Heron Therapeutics Inc (HRTX) anticipates increased competition for CINVANTI, which could pressure average selling prices and impact net revenues.
- Operating expenses, although reduced, were offset by increased legal expenses related to patent litigation.
- The company experienced inventory write-offs of $2.5 million and impairment write-offs of $2.2 million for projects no longer part of its forward-looking strategy.
- Despite achieving profitability in Q4, Heron Therapeutics Inc (HRTX) reported a net loss of $13.6 million for the full year 2024.
- The company expects some lumpiness in cash flow due to legal expenses and potential fluctuations in CINVANTI's market performance.
Good day and thank you for standing by and welcome to the Heron Therapeutics Q4 2024 conference call. (Operator Instructions) After the speaker's presentation, there will be a question-and-answer session.
And please be advised that today's conference call is being recorded. I would not like to hand a conference over to your speaker today, Melissa Jarel, executive director of Segal. Please go ahead.
Thank you, Operator, and good morning, everyone. Thank you for joining us on the Heron Therapeutics conference call this morning to discuss the company's financial results for the fourth quarter ended December 31, 2024.
With me today from Heron are Craig Collard, Chief Executive Officer, Ira Duarte, Executive Vice President, Chief Financial Officer, Bill Forbes, Executive Vice President, Chief Development Officer, and Kevin Warner, Senior Vice President, Medical Affairs, Strategy and Engagement.
For those of you participating via conference call, slides are made
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
